Bausch Health Companies Inc. vs Hitachi, Ltd.: Strategic Comparison

This in-depth comparison examines Bausch Health Companies Inc. and Hitachi, Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bausch Health Companies Inc. on its own, evaluating Hitachi, Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bausch Health Companies Inc. and Hitachi, Ltd. is widest.

On the headline numbers, Bausch Health Companies Inc. reports annual revenue of $10.3B against ~$70.9B for Hitachi, Ltd., while their respective market capitalizations stand at $2.2B and $157.8B. Bausch Health Companies Inc. is headquartered in Canada and Hitachi, Ltd. in Japan, and those different home markets shape how each company competes.

Bausch Health Companies Inc.: Bausch Health is a Canadian specialty pharmaceutical and medical device company headquartered in Laval, Quebec, and incorporated in British Columbia. It was Valeant Pharmaceuticals until July 2018, and Valeant was the Wall Street favorite that collapsed in 2015 and 2016 over drug price increases, its Philidor mail-order pharmacy arrangement and the debt it had taken on to buy drugs. Today the company sells about 1,000 products in roughly 90 countries across Salix gastroenterology, International branded generics, Solta Medical aesthetic devices, Diversified Products and Bausch + Lomb, the eye-health business it listed separately in 2022 and still owns about 88% of.

Hitachi, Ltd.: Hitachi is a Japanese industrial technology group founded in 1910 and headquartered in Chiyoda, Tokyo. It is listed on the Tokyo Stock Exchange (6501), had 287,901 employees at March 31, 2026, and is led by President and CEO Toshiaki Tokunaga, with Keiji Kojima as Executive Chairman. Many people still link the name to TVs, hard drives, or home appliances, but those businesses have been sold or are being sold. Today's Hitachi builds power grid equipment through Hitachi Energy, trains and signalling through Hitachi Rail, IT systems and digital engineering through its Digital Systems & Services sector and GlobalLogic, and industrial and building equipment through Connective Industries.

Bausch Health Companies Inc. and Hitachi, Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bausch Health Companies Inc. and Hitachi, Ltd..

Bausch Health Companies Inc. business model: Bausch Health sells prescription medicines, over-the-counter products and medical devices in about 90 countries through five reportable segments. Salix sells gastrointestinal drugs in the United States and is built around Xifaxan, which brought in $2.212B in 2025, roughly 85% of the segment. Solta Medical sells Thermage, Fraxel, Clear + Brilliant and VASERlipo aesthetic systems to clinics and earns repeat revenue on single-use treatment consumables. The International segment sells branded generics and consumer-health brands such as Bedoyecta, Bisocard, Contrave and Espaven outside the United States. Diversified Products covers U.S. neuroscience, dermatology, generics and dentistry lines. Bausch + Lomb, about 88% owned and still consolidated, contributed $5.101B of 2025 revenue from contact lenses, lens care, ophthalmic drugs and surgical equipment. Three wholesalers accounted for most U.S. sales in 2025: Cencora at 18% of revenue, McKesson at 16% and Cardinal Health at 14%.

Hitachi, Ltd. business model: Hitachi is a B2B infrastructure and IT company. It sells long-lived physical assets (transformers, HVDC converter stations, trains, signalling, elevators, semiconductor metrology tools) and then earns recurring service, maintenance, and software revenue on that installed base. Lumada is the umbrella for the data, AI, and digital services layered on top, and Hitachi reports Lumada as a growing share of total revenue. The four reporting sectors are Digital Systems & Services, Energy, Mobility, and Connective Industries. Customers are utilities, rail operators, governments, banks, and manufacturers, and many contracts run for years, which gives Hitachi a large order backlog and revenue visibility.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bausch Health Companies Inc. stack up against those of Hitachi, Ltd..

Bausch Health Companies Inc. competitive advantage: Bausch Health's strongest asset is Bausch + Lomb, the 1853-founded eye-health business it bought in 2013, listed on the NYSE and TSX in May 2022 and still owns about 88% of. That segment generated $5.101B of revenue in 2025 across contact lenses, lens care, ophthalmic pharmaceuticals and surgical equipment. In gastroenterology, Xifaxan holds a decade of outcomes data in reducing the risk of overt hepatic encephalopathy recurrence and in irritable bowel syndrome with diarrhea, supported by direct-to-consumer advertising and a specialist sales force calling on gastroenterologists and hepatologists. Solta Medical adds an installed base of Thermage and Fraxel systems that pulls recurring consumable sales, and the International segment sells roughly 1,000 products through established pharmacy channels in Poland, Mexico, Canada and other markets.

Hitachi, Ltd. competitive advantage: Hitachi's edge is owning both the operational technology and the IT. Hitachi Energy (built on ABB's former Power Grids business) is one of a handful of suppliers able to deliver HVDC links and large power transformers at scale, Hitachi Rail became a top-tier signalling supplier after buying Thales GTS in 2024, and GlobalLogic plus Hitachi's Japanese IT business supply the software. Few rivals combine all three, and the installed base of grids, trains, and IT systems feeds long-term service revenue.

Future prospects matter as much as current results. The growth strategies below explain how Bausch Health Companies Inc. and Hitachi, Ltd. each plan to expand from here.

Bausch Health Companies Inc. growth strategy: Growth spending is subordinated to the balance sheet. Bausch Health refinanced $9.6B of debt in 2025 to push out near- and medium-term maturities and directs cash flow to debt reduction, generating $1.2B of adjusted cash flow from operations for the year. Within that constraint it invests in Xifaxan direct-to-consumer advertising and sales force capacity, bought DURECT in September 2025 for about $63M upfront plus up to $350M in milestones to add larsucosterol, and is widening Solta Medical distribution, including the December 2025 purchase of Shibo Zhenmei's aesthetics distribution business in China. The Bausch + Lomb separation remains the largest potential source of value, and it is conditioned on hitting targeted leverage ratios rather than on a fixed timetable.

Hitachi, Ltd. growth strategy: Hitachi grows by attaching software and services to its installed base and by reshaping its portfolio. It is expanding Hitachi Energy factory capacity for transformers and HVDC, integrating Thales GTS into Hitachi Rail, and scaling Lumada through GlobalLogic and AI partnerships. On the portfolio side, it agreed in April 2026 to sell 80.1% of its home appliance business to Nojima for about $737 million (¥110 billion), continuing a long exit from consumer and commodity businesses.

A closer look at the financial trajectory of Bausch Health Companies Inc. and Hitachi, Ltd. rounds out the comparison.

Bausch Health Companies Inc.: FY2025 revenue was $10.266B, up $641M or 7% over 2024, split between product sales of $10.156B and other revenue of $110M. Operating costs included cost of goods sold of $2.949B, selling, general and administrative expense of $3.438B, research and development of $629M and intangible amortization of $1.001B, plus $145M of goodwill impairments in the Generics reporting unit. Income before income taxes was $367M and net income attributable to Bausch Health was $157M, against a $46M loss in 2024, helped by a $139M larger gain on debt extinguishment and held back by interest expense of $1.604B, up 16%. Debt remains the dominant line item: $20.232B of principal outstanding at December 31, 2025, or $20.817B including unamortised premiums, discounts and issuance costs, with maturities of $58M in 2026, $701M in 2027, $4.240B in 2028, $1.662B in 2029, $4.118B in 2030 and $9.453B thereafter. During 2025 the company refinanced $9.6B of debt, including April 2025 transactions that put in place a $3.0B term loan B due October 2030, a $500M revolving facility due April 2030 and $4.4B of 10.00% senior secured notes, and a $1.7B exchange offer in the fourth quarter. The first quarter of 2026 then carried a $1.426B goodwill impairment at Salix after the RED-C trial results.

Hitachi, Ltd.: Hitachi posted a ~$5.27 billion (¥787.3 billion) net loss for fiscal 2008, then the largest ever by a Japanese manufacturer. Under Takashi Kawamura and Hiroaki Nakanishi it cut loss-making consumer businesses, and later leaders sold listed subsidiaries such as Hitachi Chemical (2020), Hitachi Metals (2023), and a controlling stake in Hitachi Construction Machinery (2022). Revenue dipped from ~$72.9 billion (¥10.88 trillion) in FY2022 to ~$65.2 billion (¥9.73 trillion) in FY2023 as those units left, then climbed back to ~$71 billion (¥10.59 trillion) in FY2025 on organic growth. FY2025 adjusted EBITA was a record ~$8.78 billion (¥1.31 trillion) (12.4% margin) and net income was ~$5.38 billion (¥802.3 billion), up about 30%. In Q1 FY2026 (April-June 2026) revenue rose 20% to ~$18.2 billion (¥2,709.6 billion), helped by currency, and management raised full-year guidance.